CN109311891A - 作为jak抑制剂的吡咯并嘧啶化合物的结晶 - Google Patents
作为jak抑制剂的吡咯并嘧啶化合物的结晶 Download PDFInfo
- Publication number
- CN109311891A CN109311891A CN201780037131.9A CN201780037131A CN109311891A CN 109311891 A CN109311891 A CN 109311891A CN 201780037131 A CN201780037131 A CN 201780037131A CN 109311891 A CN109311891 A CN 109311891A
- Authority
- CN
- China
- Prior art keywords
- formulas
- compound shown
- crystallization
- crystalline
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D9/00—Crystallisation
- B01D9/005—Selection of auxiliary, e.g. for control of crystallisation nuclei, of crystal growth, of adherence to walls; Arrangements for introduction thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
Claims (12)
- PCT国内申请,权利要求书已公开。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2016104359474 | 2016-06-16 | ||
CN201610435947.4A CN107759600A (zh) | 2016-06-16 | 2016-06-16 | 作为jak抑制剂的吡咯并嘧啶化合物的结晶 |
PCT/CN2017/088429 WO2017215630A1 (zh) | 2016-06-16 | 2017-06-15 | 作为jak抑制剂的吡咯并嘧啶化合物的结晶 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109311891A true CN109311891A (zh) | 2019-02-05 |
CN109311891B CN109311891B (zh) | 2020-09-04 |
Family
ID=60664302
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610435947.4A Pending CN107759600A (zh) | 2016-06-16 | 2016-06-16 | 作为jak抑制剂的吡咯并嘧啶化合物的结晶 |
CN201780037131.9A Active CN109311891B (zh) | 2016-06-16 | 2017-06-15 | 作为jak抑制剂的吡咯并嘧啶化合物的结晶 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610435947.4A Pending CN107759600A (zh) | 2016-06-16 | 2016-06-16 | 作为jak抑制剂的吡咯并嘧啶化合物的结晶 |
Country Status (11)
Country | Link |
---|---|
US (1) | US10626118B2 (zh) |
EP (1) | EP3473626B1 (zh) |
JP (1) | JP6986032B2 (zh) |
KR (1) | KR102523564B1 (zh) |
CN (2) | CN107759600A (zh) |
AU (1) | AU2017284702B2 (zh) |
CA (1) | CA3026602A1 (zh) |
ES (1) | ES2886910T3 (zh) |
RU (1) | RU2746045C2 (zh) |
TW (1) | TWI753918B (zh) |
WO (1) | WO2017215630A1 (zh) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107513069A (zh) * | 2016-06-16 | 2017-12-26 | 正大天晴药业集团股份有限公司 | 手性吡咯并嘧啶化合物的制备方法 |
CN107759600A (zh) | 2016-06-16 | 2018-03-06 | 正大天晴药业集团股份有限公司 | 作为jak抑制剂的吡咯并嘧啶化合物的结晶 |
JP2022515272A (ja) | 2018-12-24 | 2022-02-17 | チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド | ピロロピリミジン化合物の治療的使用およびその固形医薬組成物 |
EA202192575A1 (ru) | 2019-03-21 | 2022-01-14 | Онксео | Соединения dbait в сочетании с ингибиторами киназ для лечения рака |
US20220401436A1 (en) | 2019-11-08 | 2022-12-22 | INSERM (Institute National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
EP4119562A4 (en) * | 2020-03-09 | 2024-04-24 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | USE OF A PYRROLOPYRIMIDINE COMPOUND FOR THE TREATMENT OF HEMOPHAGOCYTIC SYNDROME |
WO2022268083A1 (zh) * | 2021-06-21 | 2022-12-29 | 正大天晴药业集团股份有限公司 | 吡咯并嘧啶化合物及其药物组合物治疗慢性移植物抗宿主病的用途 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103214483A (zh) * | 2005-12-13 | 2013-07-24 | 因塞特公司 | 作为两面神激酶抑制剂的杂芳基取代的吡咯并[2,3-b]吡啶和吡咯并[2,3-b]嘧啶 |
CN105777754A (zh) * | 2014-12-16 | 2016-07-20 | 北京赛林泰医药技术有限公司 | 吡咯并嘧啶化合物 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2076516B1 (en) * | 2006-10-27 | 2013-12-11 | Signal Pharmaceuticals LLC | Solid forms comprising 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol, compositions thereof, and use therewith |
US20080312259A1 (en) * | 2007-06-13 | 2008-12-18 | Incyte Corporation | SALTS OF THE JANUS KINASE INHIBITOR (R)-3-(4-(7H-PYRROLO[2,3-d]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYLPROPANENITRILE |
CL2009001884A1 (es) * | 2008-10-02 | 2010-05-14 | Incyte Holdings Corp | Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco. |
US20130310340A1 (en) * | 2012-05-16 | 2013-11-21 | Rigel Pharmaceuticals, Inc. | Method of treating muscular degradation |
CN105218548A (zh) * | 2014-06-09 | 2016-01-06 | 上海海和药物研究开发有限公司 | 一种新型杂环化合物及其制备方法和作为激酶抑制剂的用途 |
EP3183253B1 (en) * | 2014-08-21 | 2018-06-27 | ratiopharm GmbH | Salt of (r)-3-(4-(7h-pyrrolo [2,3-d]pyrimidin-4-yl)-lh-pyrazol-l-yl)-3-cyclopentylpropanenitrile with benzenesulfonic acid |
CN107759600A (zh) | 2016-06-16 | 2018-03-06 | 正大天晴药业集团股份有限公司 | 作为jak抑制剂的吡咯并嘧啶化合物的结晶 |
-
2016
- 2016-06-16 CN CN201610435947.4A patent/CN107759600A/zh active Pending
-
2017
- 2017-06-15 JP JP2018565295A patent/JP6986032B2/ja active Active
- 2017-06-15 CN CN201780037131.9A patent/CN109311891B/zh active Active
- 2017-06-15 US US16/310,369 patent/US10626118B2/en active Active
- 2017-06-15 EP EP17812741.1A patent/EP3473626B1/en active Active
- 2017-06-15 AU AU2017284702A patent/AU2017284702B2/en active Active
- 2017-06-15 ES ES17812741T patent/ES2886910T3/es active Active
- 2017-06-15 TW TW106119959A patent/TWI753918B/zh active
- 2017-06-15 RU RU2018145948A patent/RU2746045C2/ru active
- 2017-06-15 KR KR1020197001160A patent/KR102523564B1/ko active IP Right Grant
- 2017-06-15 CA CA3026602A patent/CA3026602A1/en active Pending
- 2017-06-15 WO PCT/CN2017/088429 patent/WO2017215630A1/zh unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103214483A (zh) * | 2005-12-13 | 2013-07-24 | 因塞特公司 | 作为两面神激酶抑制剂的杂芳基取代的吡咯并[2,3-b]吡啶和吡咯并[2,3-b]嘧啶 |
CN105777754A (zh) * | 2014-12-16 | 2016-07-20 | 北京赛林泰医药技术有限公司 | 吡咯并嘧啶化合物 |
Also Published As
Publication number | Publication date |
---|---|
WO2017215630A1 (zh) | 2017-12-21 |
TWI753918B (zh) | 2022-02-01 |
CN107759600A (zh) | 2018-03-06 |
AU2017284702B2 (en) | 2021-05-06 |
JP2019521980A (ja) | 2019-08-08 |
RU2018145948A3 (zh) | 2020-10-16 |
AU2017284702A1 (en) | 2019-01-24 |
JP6986032B2 (ja) | 2021-12-22 |
ES2886910T3 (es) | 2021-12-21 |
CA3026602A1 (en) | 2017-12-21 |
EP3473626B1 (en) | 2021-08-04 |
RU2746045C2 (ru) | 2021-04-06 |
EP3473626A4 (en) | 2020-02-19 |
EP3473626A1 (en) | 2019-04-24 |
KR102523564B1 (ko) | 2023-04-19 |
KR20190017977A (ko) | 2019-02-20 |
US20190330215A1 (en) | 2019-10-31 |
CN109311891B (zh) | 2020-09-04 |
US10626118B2 (en) | 2020-04-21 |
RU2018145948A (ru) | 2020-07-16 |
TW201800413A (zh) | 2018-01-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109311891A (zh) | 作为jak抑制剂的吡咯并嘧啶化合物的结晶 | |
KR102426043B1 (ko) | 액티빈 수용체 유사 키나아제의 저해제 | |
CN107382879B (zh) | 一种嘧啶类化合物、egfr抑制剂及其应用 | |
CN109867676B (zh) | 一种吡咯并嘧啶衍生的化合物、药物组合物以及其用途 | |
CN111902417B (zh) | 一种二芳基巨环化合物、药物组合物以及其用途 | |
CN108774214A (zh) | 作为激酶抑制剂的杂环酰胺 | |
EP3124486B1 (en) | Substituted nitrogen-containing heterocyclic derivatives, pharmaceutical compositions comprising the same and applications of antitumor thereof | |
CN107531678A (zh) | Egfr抑制剂及其药学上可接受的盐和多晶型物及其应用 | |
EA027984B1 (ru) | Аминохинолины в качестве ингибиторов rip2 киназы | |
JP2021536436A (ja) | キノリン誘導体から調製される新規な阻害剤 | |
US20180179189A1 (en) | Adipate forms and compositions of biaryl inhibitors of bruton's tyrosine kinase | |
EP3307732A1 (en) | Forms and compositions of biaryl inhibitors of bruton's tyrosine kinase | |
CN109311852A (zh) | 作为egfr抑制剂的苯胺嘧啶化合物的结晶 | |
CN110869371B (zh) | 7-位取代吡咯并三嗪类化合物或其药学上可用的盐,及其制备方法和用途 | |
CN113544129A (zh) | 三环类化合物制备方法及其在医药领域的应用 | |
JP2023536892A (ja) | Jak阻害剤化合物及びその使用 | |
WO2021197467A1 (zh) | 多靶点的抗肿瘤化合物及其制备方法和应用 | |
US20230192710A1 (en) | Jak inhibitor compound and use thereof | |
CN108430987A (zh) | Pi3k抑制剂及其药学上可接受的盐和多晶型物及其应用 | |
WO2024067744A1 (zh) | 杂环取代喹唑啉及其制备方法和应用 | |
JP2023502279A (ja) | Cps1を阻害するためのピペラジン化合物 | |
CN115504980A (zh) | 嘧啶并含氮六元芳香杂环类化合物及其用途 | |
EP3941472A1 (en) | <smallcaps/>? ? ?n? ? ? ? ?crystalline and amorphous forms of-(5-((4-ethylpiperazin-1-yl)methyl)pyridine-2-yl)-5-fluoro-4-(3-isopropyl-2-methyl-2 <ns1:i>h</ns1:i>?-indazol-5-yl)pyrimidin-2-amine and its salts, and preparation methods and therapeutic uses thereof | |
CN115677831A (zh) | 拟肽类stat降解药物、组合物及应用 | |
CN116265462A (zh) | 一种具有抗肿瘤活性的杂环化合物及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20190603 Address after: No. 369, Yuzhou South Road, Lianyungang, Jiangsu Province Applicant after: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Applicant after: Lianyungang Runzhong Pharmaceutical Co.,Ltd. Applicant after: Capital Pharmaceutical Holdings (Beijing) Co., Ltd. Address before: 222062 Yuzhou South Road, Haizhou District, Lianyungang, Jiangsu 369 Applicant before: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Applicant before: Lianyungang Runzhong Pharmaceutical Co.,Ltd. Applicant before: Beijing Centaurus Biopharma Technology Co., Ltd. |
|
TA01 | Transfer of patent application right | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1260817 Country of ref document: HK |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP01 | Change in the name or title of a patent holder |
Address after: No. 369, Yuzhou South Road, Lianyungang, Jiangsu Province Patentee after: CHIA TAI TIANQING PHARMACEUTICAL GROUP Co.,Ltd. Patentee after: LIANYUNGANG RUNZHONG PHARMACEUTICAL Co.,Ltd. Patentee after: Capital Pharmaceutical Holdings (Beijing) Co.,Ltd. Address before: No. 369, Yuzhou South Road, Lianyungang, Jiangsu Province Patentee before: CHIA TAI TIANQING PHARMACEUTICAL GROUP Co.,Ltd. Patentee before: LIANYUNGANG RUNZHONG PHARMACEUTICAL Co.,Ltd. Patentee before: Shouyao holding (Beijing) Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder |